Pier Luigi Zinzani
Professor of Hematology
University of Bologna / Policlinico S. Orsola-Malpighi · Bologna, Italy
Italian MCL expert and key investigator in the CITADEL-205 trial of parsaclisib in relapsed MCL. Active in European MCL Network and multiple registration trials.
Glofitamab in Heavily Pretreated Mantle Cell Lymphoma Patients: A Multicenter Real-World Case Series.
EJHaem · Aug 1, 2026
Molecular biomarkers as key determinants of outcome in mantle cell lymphoma: results from the FIL V-RBAC trial.
Blood advances · Jul 24, 2026
First-line ibrutinib plus venetoclax for non-blastoid mantle cell lymphoma in patients ≥65 years or with TP53 mutations.
Blood · Jul 1, 2026
Real-world patient-reported symptomatic adverse events and concordance with physician assessments after CAR T-cell therapy in patients with aggressive B-cell lymphomas: a prospective study.
The Lancet. Haematology · Jun 12, 2026
A Meta-analysis Investigating Response Rates with Continuous Bruton Tyrosine Kinase Inhibitor Monotherapies in the Treatment of B Cell Lymphomas.
Oncology and therapy · Mar 7, 2026
Pirtobrutinib in relapsed or refractory mantle cell lymphoma: outcomes from the compassionate use program in Italy.
Leukemia & lymphoma · Jan 29, 2026
Overcoming barriers to referral for CAR T-cell therapy in patients with non-Hodgkin aggressive B-cell lymphomas: A Delphi consensus.
Cytotherapy · Nov 1, 2025
[The current role of CAR-T cell treatment in lymphoma therapy: focus on diffuse large cell lymphoma and mantle cell lymphoma].
Recenti progressi in medicina · May 1, 2025
Covalent Bruton tyrosine kinase inhibitors across generations: A focus on zanubrutinib.
Journal of cellular and molecular medicine · Feb 1, 2025
Brexucabtagene autoleucel in-vivo expansion and BTKi refractoriness have a negative influence on progression-free survival in mantle cell lymphoma: Results from CART-SIE study.
British journal of haematology · Feb 1, 2025
Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial.
Haematologica · Jan 1, 2025
Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network.
Lancet (London, England) · May 25, 2024
Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma.
Leukemia & lymphoma · Jan 1, 2024
Unmet needs in relapsed/refractory mantle cell lymphoma after failure of covalent Bruton's tyrosine kinase inhibitors: An Italian scenario.
Hematological oncology · Jan 1, 2024
Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prognostic factors.
Haematologica · Jan 1, 2024